June 12: The FDA gave an additional indication to the Dako PD-L1 IHC 22C3 pharmDx assay to help identify people with cervical cancer who are most likely to benefit from treatment with Merck & Co., Inc.’s Keytruda (pembrolizumab) (see brief below). The Agilent Technologies Inc. test can determine a person’s programmed cell death ligand 1 […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.